ARTICLE | Emerging Company Profile
ReproNovo: Improving reproductive health for both men and women
With a $65M series A in May, the Swiss start-up is advancing in-licensed and acquired assets backed by clinical data
September 15, 2025 9:19 PM UTC
ReproNovo is repositioning assets with existing clinical data for new indications in reproductive health, aiming to meet fertility needs in both men and women.
Switzerland-based ReproNovo S.A. has obtained rights to two assets: leflutrozole (RPN-001), an aromatase inhibitor to treat male infertility, and nolasiban (RPN-002), an oxytocin receptor antagonist for embryo implantation and adenomyosis...